BC-1 medical pressure sensitive adhesive has good drug controlled release ability and is suitable for transdermal drug delivery systems. The development of pharmaceutical preparations relies to a large extent on the development of pharmaceutical excipients. The development of a new type of polymeric pharmaceutical excipients will drive the development of a new class of dosage forms and a large number of new pharmaceutical preparations. The development of pharmaceutical pressure sensitive adhesives is critical to the development of pharmaceutical transdermal absorption formulations.
The BC-1 medical pressure sensitive adhesive is mainly prepared by reacting a polyether polyol, a polyester polyol or a mixture of the two with toluene diisocyanate. Its English name Medical pressure-sensitive adhesive BC-1. This product is a solvent-based product, which is prepared by using polyurethane resin as the main raw material and polymerizing with special crosslinking agent at 60~90 °C for 6-8 hours.
BC-1 medical pressure sensitive adhesive
has high content, good initial viscosity, strong cohesive force, high brightness, good transparency and certain gas permeability. It has no side effects on the human body and is non-toxic and non-irritating to the skin. It does not contain hexavalent chromium, benzene, ether and other systems, and is a non-toxic environmentally friendly product.
A bactericidal agent is further added to the adhesive to remove the superabsorbent of the wound exudate and the compound having an effective regenerative ability for wound healing. The adhesive can be used to prepare self-adhesive film structures in the medical field, especially for anastomotic devices, wound adhesive plasters, wound dressings, and gauze bandages.